

Freedom of Information Request: 0152

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

Queen Elizabeth Hospital

1 - In your Trust, how much did you spend on Biological and biosimilar medicines, in the past financial year ending April 2018 ?

£2,219,236

2 – Have you developed a policy on how prescribers can switch their patients to biosimilars and support them in making informed choices to save resources ?

If yes, please provide details

Yes, we are using an opt-out approach for patients and a generic letter to be used. It will be a patient choice not to receive a biosimilar rather than a decision by a clinician.

3 – Do you have any specific plans in place for the launch of biosimilar Adalimumab later in 2018 ?

Yes we are finalising an action plan

4 – Are there any agreements in place between you the Provider and CCG that would enable savings in drug costs to be made ? (For example, Gainshare agreements where the benefits associated with more efficient use of medicines not reimbursed through national prices is shared between the Provider and the Clinical Commissioning Group party to the agreement. This included agreements for the switch to biosimilar products)

Yes

If “Yes”, then please provide the following details:

Agreement	Name of specific drugs involved	Disease Area	CCG(s) included in the Gainshare agreement	Savings apportioned between Provider and the CCG(s)
1	Infliximab	All	Birmingham and Solihull CCG	100% to provider for 1 st 12 months
2	Etanercept	All	Birmingham	100% to

			and Solihull CCG	provider for 1 st 12 months
3	Rituximab	All	Birmingham and Solihull CCG	100% to provider for 1 st 12 months
4	Adalimumab	All	Birmingham and Solihull CCG	100% to provider for 1 st 12 months
5	Trastuzumab	All	Birmingham and Solihull CCG	100% to provider for 1 st 12 months

5 – Are there any other agreements with a CCG, not included in the above, for the following services ?

No

If “Yes”, then please provide the following details:

Agreement	Disease Area	CCG(s) included in the agreement	Name of specific drugs involved	Type of agreement with the Provider
1	Ophthalmology services (eg wet macular degeneration)			
2	Multiple Sclerosis			
3	Prostate Cancer			
4	Breast Cancer			
5	Haemophilia			

Heartlands, Good Hope and Solihull Hospital

1 - In your Trust, how much did you spend on Biological and biosimilar medicines, in the past financial year ending April 2018 ?

£12,013,412.77 value of issues for infliximab, etanercept, rituximab, adalimumab, trastuzumab for the financial year April 17 to March 18

2 – Have you developed a policy on how prescribers can switch their patients to biosimilars and support them in making informed choices to save resources?

If yes, please provide details

There is no standard policy on switching patients to biosimilars. There is a common process which has applied to all of the switches so far which includes early engagement with the clinical teams regarding the biosimilar, looking at the clinical data and developing a plan on how patients will be switched. However HGS will be adopting the QEHB policy in due course.

3 – Do you have any specific plans in place for the launch of biosimilar Adalimumab later in 2018 ?

These are currently in development with engagement with the clinical teams in rheumatology, dermatology and gastroenterology.

4 – Are there any agreements in place between you the Provider and CCG that would enable savings in drug costs to be made ? (For example, Gainshare agreements where the benefits associated with more efficient use of medicines not reimbursed through national prices is shared between the Provider and the Clinical Commissioning Group party to the agreement. This included agreements for the switch to biosimilar products)

Yes

If “Yes”, then please provide the following details:

Agreement	Name of specific drugs involved	Disease Area	CCG(s) included in the Gainshare agreement	Savings apportioned between Provider and the CCG(s)
1	Infliximab	Rheumatology/ Dermatology/ gastroenterology	BSol	100% for switch patients for 12 months 100% for new patients for 3 months
2	Etanercept	Rheumatology/	BSol	100% for

		Dermatology		switch patients for 12 months 100% for new patients for 3 months
3	Rituximab	Rheumatology/ Dermatology/ Oncology	BSol	100% for switch patients for 12 months 100% for new patients for 3 months
4	Adalimumab	Rheumatology/ Dermatology/ Gastroenterology	Bsol	100% for switch patients for 12 months 100% for new patients for 3 months
5	Trastuzumab	Oncology	BSol	As above

5 – Are there any other agreements with a CCG, not included in the above, for the following services ?

No

If “Yes”, then please provide the following details:

Agreement	Disease Area	CCG(s) included in the agreement	Name of specific drugs involved	Type of agreement with the Provider
1	Ophthalmology services (eg wet macular degeneration)			
2	Multiple Sclerosis			
3	Prostate Cancer			
4	Breast Cancer			
5	Haemophilia			